Peptides offer highly targeted signaling with favorable safety profiles, validated by the GLP-1 revolution. Consumer demand for proactive health, telehealth access, and expanding pipelines drive adoption. Pure-play exposure is limited; only GLP provided real-time data, so related ecosystem leaders are included for context.